ClinicalTrials.gg
CompletedNCT02097849Updated Jun 2, 2017Results posted

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

A Phase 2 interventional study of dimethyl fumarate and tetanus diphtheria toxoids vaccine in Relapsing Forms of Multiple Sclerosis, sponsored by Biogen. Completed at 14 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-06-02.

Sponsored by Biogen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
71
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis — 1 open to participants now, 1 under way, 1 of them phase 3. Dimethyl Fumarate · Multiple Sclerosis.

Enrollment
13th of 22
71 · median 86
Started
2015
with 6 others
Phase 2
3 of 22
none open now
Registered
10th of 22
by date
Lead sponsor
17 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, this one is the 13th largest by enrollment, is one of 7 that started in 2015, is one of 3 in phase 2, and was the 10th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

1 of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis is open now. Recruiting first, the newest first:

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, or all of them as a file.
02

Study summary

Primary objective is to evaluate the immune response to vaccination with tetanus diphtheria toxoids vaccine (Td) in participants with relapsing forms of Multiple Sclerosis (MS) who have been treated with Tecfidera (BG00012) versus those treated with non pegylated interferon (IFN).

Secondary objective is to evaluate the immune response to vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) [a mostly T cell-independent humoral response] and meningococcal polysaccharide diphtheria conjugate vaccine, quadrivalent (MCV4) [T cell-dependent neoantigen response].

03

Conditions studied

  • Relapsing Forms of Multiple Sclerosis

Browse trials for

Keywords

  • vaccine
  • pneumococcal
  • meningococcal
  • tetanus diphtheria
  • immune response
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have a confirmed diagnosis of relapsing remitting MS per the 2010 McDonald criteria.
  • Must have a known tetanus immunization history with most recent tetanus vaccination given 2 to 15 years prior to Screening and an anti-tetanus serum immunoglobulin titer at Screening that is less than or equal to one-half the upper limit of detection for the assay.
  • Must have been on a stable approved dose of Tecfidera (240 mg twice daily [BID]) [Group 1] for ≥6 months or on a stable approved dose of a non-pegylated IFN (e.g., Avonex, Betaseron, Rebif, Extavia) [Group 2] for ≥3 months prior to Day 1.

Key Exclusion Criteria:

  • Clinical relapse requiring treatment within 30 days prior to Day 1.
  • Pneumococcal vaccination within 5 years prior to Screening.
  • Previous exposure to meningococcal vaccines.
  • Known to Td, PPSV23, or MCV4 or their components.

NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Active comparator
    Non-Pegylated IFN Treated Plus Vaccinations

    Participants on a stable approved dose of a non pegylated IFN for ≥3 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order: Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL

    Biological: tetanus diphtheria toxoids vaccine · Biological: 23-valent pneumococcal polysaccharide vaccine · Biological: meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) · Drug: non-pegylated interferon

  • Experimental
    Tecfidera Treated Plus Vaccinations

    Participants on a stable approved dose of Tecfidera (240 mg BID) for ≥6 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order: Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL

    Drug: dimethyl fumarate · Biological: tetanus diphtheria toxoids vaccine · Biological: 23-valent pneumococcal polysaccharide vaccine · Biological: meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)

Interventions

  • Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera.

    Also known as: DMF, BG00012, Tecfidera

  • Administered as described in the treatment arm

    Also known as: Td, Tenivac

  • Administered as described in the treatment arm

    Also known as: Pneumovax 23, PPSV23

  • Biologicalmeningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)

    Administered as described in the treatment arm

    Also known as: MCV4, Menveo

  • Drugnon-pegylated interferon

    Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.

    Also known as: IFN

06

What researchers measure

Primary outcomes

  1. Percentage of Tetanus Responders (≥ 2-Fold Rise) at Day 28 Compared to Prevaccination Level

    Percentage of participants with a ≥ 2-fold rise in anti-tetanus serum immunoglobulin G (IgG) levels (responders) from prevaccination to 4 weeks after Td vaccination.

    Time frame: Up to Week 4 (Day 28) postvaccination

Secondary outcomes

  1. Percentage of Tetanus Responders (≥ 4-Fold Rise) at Day 28 Compared to Prevaccination Level

    Percentage of participants with a ≥ 4-fold rise in anti-tetanus serum IgG levels (responders) from prevaccination to 4 weeks after Td vaccination.

    Time frame: Up to Week 4 (Day 28) postvaccination

  2. Percentage of Pneumococcal Serotype 3 (≥ 2-Fold Rise) Responders Compared to Prevaccination Level

    Percentage of participants with a ≥ 2-fold rise in anti-pneumococcal serum IgG levels against serotype 3 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.

    Time frame: Up to Week 4 (Day 28) postvaccination

  3. Percentage of Pneumococcal Serotype 3 (≥ 4-Fold Rise) Responders Compared to Prevaccination Level

    Percentage of participants with a ≥ 4-fold rise in anti-pneumococcal serum IgG levels against serotype 3 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.

    Time frame: Up to Week 4 (Day 28) postvaccination

  4. Percentage of Pneumococcal Serotype 8 (≥ 2-Fold Rise) Responders Compared to Prevaccination Level

    Percentage of participants with a ≥ 2-fold rise in anti-pneumococcal serum IgG levels against serotype 8 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.

    Time frame: Up to Week 4 (Day 28) postvaccination

  5. Percentage of Pneumococcal Serotype 8 (≥ 4-Fold Rise) Responders Compared to Prevaccination Level

    Percentage of participants with a ≥ 4-fold rise in anti-pneumococcal serum IgG levels against serotype 8 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.

    Time frame: Up to Week 4 (Day 28) postvaccination

  6. Percentage of Meningococcal Serogroup C Responders (≥ 2-Fold Rise) Compared to Prevaccination Level

    Percentage of participants with a ≥ 2-fold rise in anti-meningococcal serum IgG levels against serotype C from prevaccination to 4 weeks after MCV4 vaccination.

    Time frame: Up to Week 4 (Day 28) postvaccination

  7. Percentage of Meningococcal Serogroup C Responders (≥ 4-Fold Rise) Compared to Prevaccination Level

    Percentage of participants with a ≥ 4-fold rise in anti-meningococcal serum IgG levels against serotype C from prevaccination to 4 weeks after MCV4 vaccination.

    Time frame: Up to Week 4 (Day 28) postvaccination

  8. Ratio of Serum Tetanus Level at Day 28 to Prevaccination

    Median serum titer ratios from prevaccination to 4 weeks after Td vaccination.

    Time frame: Up to Week 4 (Day 28) postvaccination

  9. Ratio of Serum Pneumococcal Antibodies (Serotype 3) Level at Day 28 to Prevaccination

    Median serum titer ratios from prevaccination to 4 weeks after PPSV23 vaccination.

    Time frame: Up to Week 4 (Day 28) postvaccination

  10. Ratio of Serum Pneumococcal Antibodies (Serotype 8) Level at Day 28 to Prevaccination

    Median serum titer ratios from prevaccination to 4 weeks after PPSV23 vaccination.

    Time frame: Up to Week 4 (Day 28) postvaccination

  11. Ratio of Serum Meningococcal Antibodies (Serogroup C) Level at Day 28 to Prevaccination

    Median serum titer ratios from prevaccination to 4 weeks after MCV4 vaccination.

    Time frame: Up to Week 4 (Day 28) postvaccination

  12. Number of Participants Experiencing Vaccination-Emergent Adverse Events (AEs) and Serious AEs

    An AE was any untoward medical occurrence that did not necessarily have a causal relationship with this treatment. A serious AE was any untoward medical occurrence that at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, could have jeopardized the participant or required intervention to prevent one of the other outcomes listed in the definition above.

    Time frame: Day 1 to Week 4

  13. Number of Participants With Shifts From Baseline in Hematology

    Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high.

    Time frame: Screening to Week 4

  14. Number of Participants With Shifts From Baseline in Blood Chemistry

    Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high.

    Time frame: Screening to Week 4

  15. Number of Participants With Abnormalities in Vital Signs

    Temperature increase: \> 38 celcius (C) or ≥ 1 C increase from baseline. Pulse increase: \> 120 beats per minute (bpm) or \> 20 bpm increase from baseline. Pulse decrease: \< 50 bpm or \> 20 bpm decrease from baseline. Systolic blood pressure (SBP) increase: \> 180 millimeters of mercury (mmHg) or \> 40 mmHg from baseline. SBP decrease: \< 90 mmHg or \> 30 mmHg decrease from baseline. Diastolic blood pressure (DBP) increase: \> 105 mmHg or \> 30 mmHg increase from baseline. DBP decrease: \< 50 mmHg or \> 20 mmHg decrease from baseline.

    Time frame: Screening to Week 4

07

Results

Posted Jun 2, 2017

Participant flow

Participant flow — Overall Study
MilestoneNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Started3338
Completed3338
Not completed00

Outcome measures

PrimaryPercentage of Tetanus Responders (≥ 2-Fold Rise) at Day 28 Compared to Prevaccination Level

Percentage of participants with a ≥ 2-fold rise in anti-tetanus serum immunoglobulin G (IgG) levels (responders) from prevaccination to 4 weeks after Td vaccination.

Time frame:
Up to Week 4 (Day 28) postvaccination
Reported as:
Number · percentage of participants
Percentage of Tetanus Responders (≥ 2-Fold Rise) at Day 28 Compared to Prevaccination Level
percentage of participantsNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Percentage of Tetanus Responders (≥ 2-Fold Rise) at Day 28 Compared to Prevaccination Level73 (54 to 87)68 (51 to 82)
Statistical analysis
  • Non-Pegylated IFN Treated Plus Vaccinations vs Tecfidera Treated Plus Vaccinations · Clopper-Pearson Exact · p = 0.692 · Difference in proportion: -0.04 · 95% CI -0.27 to 0.19
SecondaryPercentage of Tetanus Responders (≥ 4-Fold Rise) at Day 28 Compared to Prevaccination Level

Percentage of participants with a ≥ 4-fold rise in anti-tetanus serum IgG levels (responders) from prevaccination to 4 weeks after Td vaccination.

Time frame:
Up to Week 4 (Day 28) postvaccination
Reported as:
Number · percentage of participants
Percentage of Tetanus Responders (≥ 4-Fold Rise) at Day 28 Compared to Prevaccination Level
percentage of participantsNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Percentage of Tetanus Responders (≥ 4-Fold Rise) at Day 28 Compared to Prevaccination Level61 (42 to 77)42 (26 to 59)
Statistical analysis
  • Non-Pegylated IFN Treated Plus Vaccinations vs Tecfidera Treated Plus Vaccinations · Clopper-Pearson Exact · p = 0.120 · Difference in proportion: -0.19 · 95% CI -0.41 to 0.05
SecondaryPercentage of Pneumococcal Serotype 3 (≥ 2-Fold Rise) Responders Compared to Prevaccination Level

Percentage of participants with a ≥ 2-fold rise in anti-pneumococcal serum IgG levels against serotype 3 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.

Time frame:
Up to Week 4 (Day 28) postvaccination
Reported as:
Number · percentage of participants
Percentage of Pneumococcal Serotype 3 (≥ 2-Fold Rise) Responders Compared to Prevaccination Level
percentage of participantsNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Percentage of Pneumococcal Serotype 3 (≥ 2-Fold Rise) Responders Compared to Prevaccination Level79 (61 to 91)66 (49 to 80)
Statistical analysis
  • Non-Pegylated IFN Treated Plus Vaccinations vs Tecfidera Treated Plus Vaccinations · Clopper-Pearson Exact · p = 0.225 · Difference in proportions: -0.13 · 95% CI -0.35 to 0.10
SecondaryPercentage of Pneumococcal Serotype 3 (≥ 4-Fold Rise) Responders Compared to Prevaccination Level

Percentage of participants with a ≥ 4-fold rise in anti-pneumococcal serum IgG levels against serotype 3 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.

Time frame:
Up to Week 4 (Day 28) postvaccination
Reported as:
Number · percentage of participants
Percentage of Pneumococcal Serotype 3 (≥ 4-Fold Rise) Responders Compared to Prevaccination Level
percentage of participantsNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Percentage of Pneumococcal Serotype 3 (≥ 4-Fold Rise) Responders Compared to Prevaccination Level70 (51 to 84)47 (31 to 64)
Statistical analysis
  • Non-Pegylated IFN Treated Plus Vaccinations vs Tecfidera Treated Plus Vaccinations · Clopper-Pearson Exact · p = 0.057 · Difference in proportions: -0.22 · 95% CI -0.44 to 0.01
SecondaryPercentage of Pneumococcal Serotype 8 (≥ 2-Fold Rise) Responders Compared to Prevaccination Level

Percentage of participants with a ≥ 2-fold rise in anti-pneumococcal serum IgG levels against serotype 8 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.

Time frame:
Up to Week 4 (Day 28) postvaccination
Reported as:
Number · percentage of participants
Percentage of Pneumococcal Serotype 8 (≥ 2-Fold Rise) Responders Compared to Prevaccination Level
percentage of participantsNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Percentage of Pneumococcal Serotype 8 (≥ 2-Fold Rise) Responders Compared to Prevaccination Level88 (72 to 97)95 (82 to 99)
Statistical analysis
  • Non-Pegylated IFN Treated Plus Vaccinations vs Tecfidera Treated Plus Vaccinations · Clopper-Pearson Exact · p = 0.300 · Difference in proportions: 0.07 · 95% CI -0.16 to 0.30
SecondaryPercentage of Pneumococcal Serotype 8 (≥ 4-Fold Rise) Responders Compared to Prevaccination Level

Percentage of participants with a ≥ 4-fold rise in anti-pneumococcal serum IgG levels against serotype 8 from prevaccination to 4 weeks (28 days) after PPSV23 vaccination.

Time frame:
Up to Week 4 (Day 28) postvaccination
Reported as:
Number · percentage of participants
Percentage of Pneumococcal Serotype 8 (≥ 4-Fold Rise) Responders Compared to Prevaccination Level
percentage of participantsNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Percentage of Pneumococcal Serotype 8 (≥ 4-Fold Rise) Responders Compared to Prevaccination Level85 (68 to 95)82 (66 to 92)
Statistical analysis
  • Non-Pegylated IFN Treated Plus Vaccinations vs Tecfidera Treated Plus Vaccinations · Clopper-Pearson Exact · p = 0.714 · Difference in proportions: -0.03 · 95% CI -0.26 to 0.20
SecondaryPercentage of Meningococcal Serogroup C Responders (≥ 2-Fold Rise) Compared to Prevaccination Level

Percentage of participants with a ≥ 2-fold rise in anti-meningococcal serum IgG levels against serotype C from prevaccination to 4 weeks after MCV4 vaccination.

Time frame:
Up to Week 4 (Day 28) postvaccination
Reported as:
Number · percentage of participants
Percentage of Meningococcal Serogroup C Responders (≥ 2-Fold Rise) Compared to Prevaccination Level
percentage of participantsNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Percentage of Meningococcal Serogroup C Responders (≥ 2-Fold Rise) Compared to Prevaccination Level53 (35 to 71)53 (36 to 69)
Statistical analysis
  • Non-Pegylated IFN Treated Plus Vaccinations vs Tecfidera Treated Plus Vaccinations · Clopper-Pearson Exact · p = 0.967 · Difference in proportions: 0 · 95% CI -0.24 to 0.23
SecondaryPercentage of Meningococcal Serogroup C Responders (≥ 4-Fold Rise) Compared to Prevaccination Level

Percentage of participants with a ≥ 4-fold rise in anti-meningococcal serum IgG levels against serotype C from prevaccination to 4 weeks after MCV4 vaccination.

Time frame:
Up to Week 4 (Day 28) postvaccination
Reported as:
Number · percentage of participants
Percentage of Meningococcal Serogroup C Responders (≥ 4-Fold Rise) Compared to Prevaccination Level
percentage of participantsNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Percentage of Meningococcal Serogroup C Responders (≥ 4-Fold Rise) Compared to Prevaccination Level38 (21 to 56)37 (22 to 54)
Statistical analysis
  • Non-Pegylated IFN Treated Plus Vaccinations vs Tecfidera Treated Plus Vaccinations · Clopper-Pearson Exact · p = 0.955 · Difference in proportions: -0.01 · 95% CI -0.24 to 0.22
SecondaryRatio of Serum Tetanus Level at Day 28 to Prevaccination

Median serum titer ratios from prevaccination to 4 weeks after Td vaccination.

Time frame:
Up to Week 4 (Day 28) postvaccination
Reported as:
Median · ratio
Ratio of Serum Tetanus Level at Day 28 to Prevaccination
ratioNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Ratio of Serum Tetanus Level at Day 28 to Prevaccination6.128 (2.828 to 8.139)4.463 (1.955 to 8.244)
SecondaryRatio of Serum Pneumococcal Antibodies (Serotype 3) Level at Day 28 to Prevaccination

Median serum titer ratios from prevaccination to 4 weeks after PPSV23 vaccination.

Time frame:
Up to Week 4 (Day 28) postvaccination
Reported as:
Median · ratio
Ratio of Serum Pneumococcal Antibodies (Serotype 3) Level at Day 28 to Prevaccination
ratioNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Ratio of Serum Pneumococcal Antibodies (Serotype 3) Level at Day 28 to Prevaccination9.667 (4.537 to 18.000)4.741 (2.000 to 11.000)
SecondaryRatio of Serum Pneumococcal Antibodies (Serotype 8) Level at Day 28 to Prevaccination

Median serum titer ratios from prevaccination to 4 weeks after PPSV23 vaccination.

Time frame:
Up to Week 4 (Day 28) postvaccination
Reported as:
Median · ratio
Ratio of Serum Pneumococcal Antibodies (Serotype 8) Level at Day 28 to Prevaccination
ratioNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Ratio of Serum Pneumococcal Antibodies (Serotype 8) Level at Day 28 to Prevaccination27.000 (12.750 to 49.286)13.845 (6.000 to 28.250)
SecondaryRatio of Serum Meningococcal Antibodies (Serogroup C) Level at Day 28 to Prevaccination

Median serum titer ratios from prevaccination to 4 weeks after MCV4 vaccination.

Time frame:
Up to Week 4 (Day 28) postvaccination
Reported as:
Median · ratio
Ratio of Serum Meningococcal Antibodies (Serogroup C) Level at Day 28 to Prevaccination
ratioNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Ratio of Serum Meningococcal Antibodies (Serogroup C) Level at Day 28 to Prevaccination3.300 (1.000 to 11.159)3.408 (1.000 to 8.600)
SecondaryNumber of Participants Experiencing Vaccination-Emergent Adverse Events (AEs) and Serious AEs

An AE was any untoward medical occurrence that did not necessarily have a causal relationship with this treatment. A serious AE was any untoward medical occurrence that at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, could have jeopardized the participant or required intervention to prevent one of the other outcomes listed in the definition above.

Time frame:
Day 1 to Week 4
Reported as:
Number · participants
Number of Participants Experiencing Vaccination-Emergent Adverse Events (AEs) and Serious AEs
participantsNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Any Event1816
Moderate or Severe Event97
Severe Event20
Event Related to Existing Therapy33
Serious Event00
Serious Event Related to Existing Therapy00
Serious Event Related to Td Vaccine00
Serious Event Related to PPSV23 Vaccine00
Serious Event Related to MCV4 Vaccine00
Withdrew From Study Due to an Event00
SecondaryNumber of Participants With Shifts From Baseline in Hematology

Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high.

Time frame:
Screening to Week 4
Reported as:
Number · participants
Number of Participants With Shifts From Baseline in Hematology
participantsNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Hemoglobin: Shift to Low; n=28, 3610
Hemoglobin: Shift to High; n=32, 3800
Hematocrit: Shift to Low; n=31, 3721
Hematocrit: Shift to High; n=32, 3800
Red Blood Cell Count: Shift to Low; n=25, 3214
Red Blood Cell Count: Shift to High; n=33, 3700
White Blood Cell Count: Shift to Low; n=27, 3024
White Blood Cell Count: Shift to High; n=33, 3820
Neutrophils: Shift to Low; n=27, 3432
Neutrophils: Shift to High; n=33, 3720
Basophils: Shift to Low; n=33, 3800
Basophils: Shift to High; n=33, 3800
Monocytes: Shift to Low; n=33, 3802
Monocytes: Shift to High; n=33, 3820
Lymphocytes: Shift to Low; n=33, 2241
Lymphocytes: Shift to High; n=33, 3800
Eosinophils: Shift to Low; n=33, 3800
Eosinophils: Shift to High; n=33, 3800
Platelet Count: Shift to Low; n=31, 3810
Platelet Count: Shift to High; n=32, 3700
SecondaryNumber of Participants With Shifts From Baseline in Blood Chemistry

Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high.

Time frame:
Screening to Week 4
Reported as:
Number · participants
Number of Participants With Shifts From Baseline in Blood Chemistry
participantsNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Alanine Aminotransferase: Shift to Low; n=33, 3800
Alanine Aminotransferase: Shift to High; n=30, 3521
Aspartate Aminotransferase: Shift to Low; n=33, 3700
Aspartate Aminotransferase: Shift to High; n=33,3610
Total Bilirubin: Shift to Low; n=32, 3701
Total Bilirubin: Shift to High; n=33, 3800
Gamma-glutamyl Transferase: Shift to Low; n=33, 3800
Gamma-glutamyl Transferase: Shift to High; n=33,3800
Blood Urea Nitrogen: Shift to Low; n=33, 3800
Blood Urea Nitrogen: Shift to High; n=33, 3811
Creatinine: Shift to Low; n=33, 3800
Creatinine: Shift to High; n=33, 3700
Sodium: Shift to Low; n=33, 3800
Sodium: Shift to High; n=33, 3800
Potassium: Shift to Low; n=33, 3800
Potassium: Shift to High; n=33, 3800
Chloride: Shift to Low; n=33, 3810
Chloride: Shift to High; n=33, 3800
SecondaryNumber of Participants With Abnormalities in Vital Signs

Temperature increase: \> 38 celcius (C) or ≥ 1 C increase from baseline. Pulse increase: \> 120 beats per minute (bpm) or \> 20 bpm increase from baseline. Pulse decrease: \< 50 bpm or \> 20 bpm decrease from baseline. Systolic blood pressure (SBP) increase: \> 180 millimeters of mercury (mmHg) or \> 40 mmHg from baseline. SBP decrease: \< 90 mmHg or \> 30 mmHg decrease from baseline. Diastolic blood pressure (DBP) increase: \> 105 mmHg or \> 30 mmHg increase from baseline. DBP decrease: \< 50 mmHg or \> 20 mmHg decrease from baseline.

Time frame:
Screening to Week 4
Reported as:
Number · participants
Number of Participants With Abnormalities in Vital Signs
participantsNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Temperature Increase00
Pulse Increase11
Pulse Decrease00
SBP Increase10
SBP Decrease00
DBP Increase01
DBP Decrease00

Adverse events

Collected over SAEs: Screening (Within 28 Days Before Day 1) up to Week 4 (Day 28 ±3 Days) or Early Withdrawal. AEs: Day 1 up to Week 4 (Day 28 ±3 Days) or Early Withdrawal. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Non-Pegylated IFN Treated Plus Vaccinations—0/33 (0%)14/33 (42.4%)
Tecfidera Treated Plus Vaccinations—0/38 (0%)11/38 (28.9%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventNon-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus Vaccinations
Injection site painGeneral disorders7/338/38
Injection site erythemaGeneral disorders4/335/38
Injection site swellingGeneral disorders3/333/38
PainGeneral disorders3/331/38
PyrexiaGeneral disorders2/332/38
Urinary tract infectionInfections and infestations2/330/38
ArthralgiaMusculoskeletal and connective tissue disorders2/330/38
Back painMusculoskeletal and connective tissue disorders2/330/38
HeadacheNervous system disorders2/331/38
RashSkin and subcutaneous tissue disorders2/330/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)Non-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus VaccinationsTotal
Mean44.7 ± 7.7745.9 ± 6.1045.3 ± 6.91
Sex: Female, Male
Sex: Female, Male(Participants)Non-Pegylated IFN Treated Plus VaccinationsTecfidera Treated Plus VaccinationsTotal
Female273461
Male6410
08

Study locations

14 sites
  • Research Site
    Gilbert, Arizona 85234, United States
  • Research Site
    Thornton, Colorado 80233, United States
  • Research Site
    Fort Lauderdale, Florida 33312, United States
  • Research Site
    Sarasota, Florida 34243, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Lexington, Kentucky 40513, United States
  • Research Site
    Auburn, Maine 04210, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Charlotte, North Carolina 28203, United States
  • Research Site
    Akron, Ohio 44320, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Dayton, Ohio 45417, United States
  • Research Site
    Round Rock, Texas 78761, United States
  • Research Site
    San Antonio, Texas 78258, United States
09

References and documents

Publications

  • von Hehn C, Howard J, Liu S, Meka V, Pultz J, Mehta D, Prada C, Ray S, Edwards MR, Sheikh SI. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2017 Nov 15;5(1):e409. doi: 10.1212/NXI.0000000000000409. eCollection 2018 Jan. PubMed 29159204 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in May 2016, 14 months.

Results were first posted in Jun 2017, 1 year 1 month after primary completion.

Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 14 months is below that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2014
First posted
Mar 27, 2014
StartActual
Feb 28, 2015
Primary completionActual
May 2, 2016
CompletionActual
May 2, 2016
Results first posted
Jun 2, 2017
Last update
Jun 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02097849
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Mar 27, 2014
Start date
Feb 28, 2015
Primary completion
May 2, 2016
Completion
May 2, 2016
Results posted
Jun 2, 2017
Last update
Jun 2, 2017

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion